Clinical Trial Update: Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study [Phase 2]

View source ↗

Summary

Phase 2 single-arm trial evaluating anlotinib with a PD-1/PD-L1 inhibitor as sequential therapy following thoracic radiotherapy after induction chemotherapy in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• PD-1/PD-L1 inhibitor

Snippet

Sponsor: Xiaorong Dong | Conditions: NSCLC, Anlotinib | Phase 2 | Status: UNKNOWN